SNOW
Snowflake Inc.
(NYSE: SNOW)
Balfour Capital Group has issued a buy recommendation
for Snowflake (SNOW)Â on May 21st, 2025
Snowflake Inc. is a cloud-based data platform that enables organizations to consolidate, store, and analyze data across various public clouds. Its platform supports applications in data warehousing, data lakes, data engineering, data science, and data sharing. Snowflake’s architecture separates storage and compute, allowing for scalable and flexible data management solutions.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $182.20 on May 21st, 2025.
- Our designated price target stands at $235.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

2025 Q4 EARNING REPORT
A Q4 report evaluates company financials for investors.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
XBalfour Capital Group wants to clarify that our recommendation to Buy Snowflake Inc. (NYSE: SNOW)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
OTIS
Otis Worldwide Corporation
(NYSE: OTIS)
Balfour Capital Group has issued a buy recommendation
for Otis Worldwide Corporation (OTIS)Â on April 28th, 2025
Otis Worldwide Corporation is the world’s leading manufacturer, installer, and servicer of elevators, escalators, and moving walkways. Headquartered in Farmington, Connecticut, Otis operates globally, maintaining approximately 2.4 million units and moving 2.4 billion people daily. The company offers a range of products for residential, commercial, and infrastructure projects, including its Gen2, Gen3, Gen360, and SkyRise elevator systems. Otis was originally part of United Technologies but became an independent entity in April 2020.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $92.93 on April 28th, 2025.
- Our designated price target stands at $124.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
XBalfour Capital Group wants to clarify that our recommendation to Buy Otis Worldwide Corporation (NYSE:OTIS)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
ABT
Abbott Laboratories
(NYSE: ABT)
Balfour Capital Group has issued a buy recommendation
for Abbott Laboratories (ABT)Â on April 28th, 2025
Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of medical products and services. Its diversified portfolio includes diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals, serving customers in more than 160 countries. Abbott is known for innovations such as the FreeStyle Libre glucose monitoring system and structural heart devices.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $129.95 on April 28th, 2025.
- Our designated price target stands at $176.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
XBalfour Capital Group wants to clarify that our recommendation to Buy Abbott Laboratories (NYSE: ABT)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
HLT
Hilton Worldwide Holdings Inc.
(NYSE: HLT)
Balfour Capital Group has issued a buy recommendation
for Hilton Worldwide Holdings Inc. (HLT)Â on April 28th, 2025
Hilton Worldwide Holdings Inc. is a global hospitality company that manages, franchises, owns, and leases hotels and resorts. Its portfolio encompasses over 24 brands, including Waldorf Astoria, Conrad, Hilton Hotels & Resorts, DoubleTree, and Hampton by Hilton. As of December 31, 2024, Hilton operated more than 8,400 properties with over 1.25 million rooms across 140 countries and territories.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $221.25 on April 28th, 2025.
- Our designated price target stands at $265.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

2024 Q4 EARNING REPORT
A Q4 report evaluates company financials for investors.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
XBalfour Capital Group wants to clarify that our recommendation to Buy Hilton Worldwide Holdings Inc. (NYSE: HLT)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
SAP
SAP SE
(NYSE:SAP)
Balfour Capital Group has issued a buy recommendation
for SAP SE (SAP)Â on April 22nd, 2025
SAP SE is a leading global provider of enterprise application software and business AI solutions. Headquartered in Walldorf, Germany, SAP offers a wide range of solutions, including enterprise resource planning (ERP), financial management, supply chain operations, human capital management, and customer experience. The company serves organizations of all sizes across various industries, helping them operate efficiently and adapt to changing business needs.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $250.54 on April 22nd, 2025.
- Our designated price target stands at $320.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

2024 Q4 EARNING REPORT
A Q4 report evaluates company financials for investors.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
XBalfour Capital Group wants to clarify that our recommendation to Buy SAP SE (NYSE: SAP)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
INTU
Intuit Inc.
(NASDAQ: INTU)
Balfour Capital Group has issued a buy recommendation
for Intuit Inc. (INTU) on April 22nd, 2025
Intuit Inc. is a leading American financial software company headquartered in Mountain View, California. Founded in 1983, Intuit specializes in developing and marketing financial management, accounting, and tax preparation software for small and medium-sized businesses, financial institutions, and individual consumers. Its flagship products include TurboTax (tax preparation), QuickBooks (accounting), Credit Karma (credit monitoring and personal finance), and Mailchimp (email marketing). The company serves approximately 100 million customers worldwide and has integrated artificial intelligence into its platforms to enhance user experience and efficiency.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $568.84 on April 22nd, 2025.
- Our designated price target stands at $690.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

2025 Q2 EARNING REPORT
A Q2 report evaluates company financials for investors.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
Balfour Capital Group wants to clarify that our recommendation to Buy Intuit Inc. (NASDAQ: INTU)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
BSX
Boston Scientific Corporation
(NYSE: BSX)
Balfour Capital Group has issued a buy recommendation
for Boston Scientific Corporation (BSX) on April 22nd, 2025
Boston Scientific is a global medical technology company that develops, manufactures, and markets minimally invasive medical devices. Its products are used in various interventional medical specialties, including cardiology, electrophysiology, endoscopy, urology, gynecology, and neuromodulation. The company’s mission is to transform lives through innovative medical solutions that improve patient health worldwide.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $94.50 on April 22nd, 2025.
- Our designated price target stands at $130.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

2024 Q4 EARNING REPORT
A Q4 report evaluates company financials for investors.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
Balfour Capital Group wants to clarify that our recommendation to Buy Boston Scientific Corporation (NYSE: BSX)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
ANF
Abercrombie & Fitch Co.
(NYSE: ANF)
Balfour Capital Group has issued a buy recommendation
for Abercrombie & Fitch Co. (ANF)Â on April 10th, 2025
Abercrombie & Fitch Co. is a global specialty retailer offering a wide range of apparel, accessories, and personal care products. The company’s brands include Abercrombie & Fitch, abercrombie kids, Hollister Co., Gilly Hicks, and YPB. They cater to men, women, and children, focusing on casual wear and lifestyle products.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $66.94 on April 10th, 2025.
- Our designated price target stands at $87.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

2024 Q4 EARNING REPORT
A Q4 report evaluates company financials for investors.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
Balfour Capital Group wants to clarify that our recommendation to Buy Abercrombie & Fitch Co. (NYSE: ANF)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
TPR
Tapestry, Inc.
(NYSE: TPR)
Balfour Capital Group has issued a buy recommendation
for Tapestry, Inc. (TPR) on April 10th, 2025
Tapestry, Inc. is a New York-based house of modern luxury accessories and lifestyle brands, including Coach, Kate Spade, and Stuart Weitzman. The company specializes in offering high-quality handbags, footwear, and accessories.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $60.60 on April 10th, 2025.
- Our designated price target stands at $80.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

2025 Q2 EARNING REPORT
A Q2 report evaluates company financials for investors.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
Balfour Capital Group wants to clarify that our recommendation to Buy Tapestry, Inc. (NYSE: TPR)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
CLX
The Clorox Company
(NYSE: CLX)
Balfour Capital Group has issued a buy recommendation
for The Clorox Company (CLX) on April 7th, 2025
The Clorox Company, founded in 1913 and headquartered in Oakland, California, is a leading multinational manufacturer and marketer of consumer and professional products. Its diverse portfolio includes well-known brands such as Clorox® bleach and cleaning products, Pine-Sol® cleaners, Liquid-Plumr® clog removers, Kingsford® charcoal, Hidden Valley® dressings and sauces, Brita® water filters, Glad® bags and wraps, and Burt’s Bees® natural personal care products. Clorox’s products are sold in over 100 countries, aiming to champion people to be well and thrive every single day.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $143.86 on April 7th, 2025.
- Our designated price target stands at $205.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More

ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More

ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More

2025 Q2 EARNING REPORT
A Q2 report evaluates company financials for investors.
View More

THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
Balfour Capital Group wants to clarify that our recommendation to Buy The Clorox Company (NYSE: CLX)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*